5NG: [[(2~{S},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(3~{R})-4-[[3-[2-[2-[3-[[(2~{R})-4-[[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-4-oxidanyl-3-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxy-3,3-dimethyl-2-oxidanyl-butanoyl]amino]propanoylamino]ethyldisulfanyl]ethylamino]-3-oxidanylidene-propyl]amino]-2,2-dimethyl-3-oxidanyl-4-oxidanylidene-butyl] hydrogen phosphate
5NG is a Ligand Of Interest in 9EMO designated by the Author
| Best-fitted instance in this entry |
| Other instances in this entry |
| Best-fitted instance in this entry |
| Best-fitted PDB instances with same target (top 5) |
| Best-fitted instance in this entry |
| Best-fitted PDB instances with different target (top 5) |
| Identifier | Ranking for goodness of fit | Ranking for geometry | Real space R factor | Real space correlation coefficient | RMSZ-bond-length | RMSZ-bond-angle | Outliers of bond length | Outliers of bond angle | Atomic clashes | Stereochemical errors | Model completeness | Average occupancy |
|---|
| 9EMO_5NG_A_501 | 46% | 46% | 0.139 | 0.872 | 1.03 | 1.05 | 3 | 12 | 0 | 0 | 100% | 1 |
| 9EMD_5NG_A_802 | 59% | 47% | 0.126 | 0.906 | 0.97 | 1.06 | - | 9 | 0 | 0 | 100% | 1 |
| 9EMT_5NG_A_401 | 54% | 48% | 0.142 | 0.907 | 0.97 | 1.02 | 4 | 9 | 1 | 0 | 100% | 0.5 |
| 8XJH_5NG_A_302 | 90% | 30% | 0.074 | 0.956 | 1.14 | 1.62 | 2 | 13 | 7 | 0 | 100% | 1 |
| 6C37_5NG_A_301 | 81% | 17% | 0.078 | 0.972 | 2.47 | 1.19 | 18 | 7 | 4 | 0 | 77% | 0.953 |
| 7OVV_5NG_B_301 | 72% | 4% | 0.128 | 0.953 | 3.68 | 2.19 | 31 | 22 | 7 | 0 | 100% | 1 |
| 8VR6_5NG_A_201 | 71% | 56% | 0.104 | 0.925 | 0.72 | 0.96 | 3 | 7 | 0 | 0 | 100% | 1 |
